Log in

NASDAQ:XENE - Xenon Pharmaceuticals Stock Price, Forecast & News

$13.85
+0.08 (+0.58 %)
(As of 02/28/2020 03:39 AM ET)
Today's Range
$13.18
Now: $13.85
$14.28
50-Day Range
$13.77
MA: $15.92
$17.57
52-Week Range
$7.88
Now: $13.85
$18.45
Volume303,445 shs
Average Volume315,619 shs
Market Capitalization$358.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$310,000.00
Book Value$3.79 per share

Profitability

Net Income$-34,500,000.00

Miscellaneous

Employees89
Market Cap$358.29 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.


Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) posted its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks' consensus estimate of ($0.49) by $0.16. The biopharmaceutical company had revenue of $3.50 million for the quarter. View Xenon Pharmaceuticals' Earnings History.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xenon Pharmaceuticals.

What price target have analysts set for XENE?

3 brokers have issued twelve-month price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $18.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $21.50 in the next year. This suggests a possible upside of 55.2% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.

What is the consensus analysts' recommendation for Xenon Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News headlines about XENE stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Xenon Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Xenon Pharmaceuticals.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 394,200 shares, a decrease of 8.3% from the January 15th total of 429,800 shares. Based on an average daily volume of 214,600 shares, the short-interest ratio is presently 1.8 days. Currently, 1.6% of the shares of the stock are sold short. View Xenon Pharmaceuticals' Current Options Chain.

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the folowing people:
  • Simon Neil Pimstone, Chief Executive Officer & Director
  • Ian C. Mortimer, President, Chief Financial Officer & Secretary
  • Ernesto Aycardi, Chief Medical Officer
  • Robin Sherrington, Executive VP-Business & Corporate Development
  • Charles J. Cohen, Vice President-Biological Sciences

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.53%), NEA Management Company LLC (3.83%), Point72 Asset Management L.P. (3.31%), Renaissance Technologies LLC (2.30%), Parkman Healthcare Partners LLC (2.27%) and Granite Point Capital Management L.P. (1.05%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Granite Point Capital Management L.P., Russell Investments Group Ltd., Bank of New York Mellon Corp, California Public Employees Retirement System and Bank of Montreal Can. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Insider Buying and Selling for Xenon Pharmaceuticals.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, NEA Management Company LLC, Ikarian Capital LLC, BVF Inc. IL, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Marshall Wace LLP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Xenon Pharmaceuticals.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $13.85.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $358.29 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is http://www.xenon-pharma.com/.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]


MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  327 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel